DB:1TM

Stock Analysis Report

Executive Summary

Mithra Pharmaceuticals S.A. develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally.

Rewards

Revenue is forecast to grow 34.33% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year



Snowflake Analysis

Mediocre balance sheet with limited growth.


Similar Companies

Share Price & News

How has Mithra Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1TM has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-1.3%

1TM

0.9%

DE Pharmaceuticals

1.0%

DE Market


1 Year Return

11.1%

1TM

10.3%

DE Pharmaceuticals

15.7%

DE Market

Return vs Industry: 1TM exceeded the German Pharmaceuticals industry which returned 10.3% over the past year.

Return vs Market: 1TM underperformed the German Market which returned 15.7% over the past year.


Shareholder returns

1TMIndustryMarket
7 Day-1.3%0.9%1.0%
30 Day-2.7%-2.0%1.0%
90 Day0.8%4.2%6.7%
1 Year11.1%11.1%14.0%10.3%19.3%15.7%
3 Year201.6%201.6%37.4%21.6%19.5%8.9%
5 Yearn/a37.9%14.1%36.9%18.3%

Price Volatility Vs. Market

How volatile is Mithra Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Mithra Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

15.56x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 1TM's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 1TM's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 1TM is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: 1TM is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1TM's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1TM is overvalued based on its PB Ratio (15.6x) compared to the DE Pharmaceuticals industry average (2x).


Next Steps

Future Growth

How is Mithra Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

76.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1TM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 1TM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 1TM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 1TM's revenue (34.3% per year) is forecast to grow faster than the German market (4.9% per year).

High Growth Revenue: 1TM's revenue (34.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 1TM's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Mithra Pharmaceuticals performed over the past 5 years?

-42.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1TM is currently unprofitable.

Growing Profit Margin: 1TM is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 1TM is unprofitable, and losses have increased over the past 5 years at a rate of -42.1% per year.

Accelerating Growth: Unable to compare 1TM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1TM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.3%).


Return on Equity

High ROE: 1TM has a negative Return on Equity (-133.51%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Mithra Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: 1TM's short term assets (€101.3M) exceed its short term liabilities (€32.3M).

Long Term Liabilities: 1TM's short term assets (€101.3M) do not cover its long term liabilities (€274.1M).


Debt to Equity History and Analysis

Debt Level: 1TM's debt to equity ratio (363.3%) is considered high.

Reducing Debt: 1TM's debt to equity ratio has increased from 123.8% to 363.3% over the past 5 years.


Balance Sheet

Inventory Level: 1TM has a high level of physical assets or inventory.

Debt Coverage by Assets: 1TM's debt is not covered by short term assets (assets are 0.4x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 1TM has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 1TM has sufficient cash runway for 1.716811 years if free cash flow continues to grow at historical rates of 24% each year.


Next Steps

Dividend

What is Mithra Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

company0%marketbottom25%1.3%markettop25%3.6%industryaverage3.0%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 1TM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 1TM's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1TM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1TM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: 1TM is not paying a notable dividend for the German market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1TM's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Mithra Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

1.8yrs

Average management tenure


CEO

Francois Fornieri 0

0yrs

Tenure

0

Mr. Francois Fornieri served as a Director of VOO until March 29, 2017. Mr. Fornieri serves as the Chief Executive Officer and Chief Business Development Officer at Mithra Pharmaceuticals SA. Mr. Fornieri  ...


Management Age and Tenure

1.8yrs

Average Tenure

Experienced Management: 1TM's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Age and Tenure

3.3yrs

Average Tenure

51yo

Average Age

Experienced Board: 1TM's board of directors are considered experienced (3.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.2%.


Management Team

  • Graham Dixon (58yo)

    Chief Scientific Officer

    • Tenure: 0.4yrs
  • Jean-Michel Foidart

    President of the Scientific Advisory Board & Executive Director

    • Tenure: 0yrs
    • Compensation: €7.12k
  • Francois Fornieri

    CEO, Chief Business Development Officer & Executive Director

    • Tenure: 0yrs
  • Jan Van Der Auwera

    Chief Marketing Officer

    • Tenure: 0yrs
  • Michaël Dillen

    Chief Legal Officer

    • Tenure: 2.8yrs
  • Christophe Maréchal

    Chief Financial Officer

    • Tenure: 2.8yrs
  • Alexandra Deschner

    Investor Relations Officer

    • Tenure: 0.8yrs
  • Benjamin Brands

    Chief Supply Chain Officer

    • Tenure: 0yrs
  • Patrick Kellens

    Chief Information Officer

    • Tenure: 0yrs

Board Members

  • Marc Armand Alice André Coucke (54yo)

    Non-Executive Chairman

    • Tenure: 3.3yrs
    • Compensation: €41.25k
  • Jean-Michel Foidart

    President of the Scientific Advisory Board & Executive Director

    • Tenure: 0yrs
    • Compensation: €7.12k
  • Philippe Suinen

    Independent Director

    • Tenure: 0yrs
    • Compensation: €25.00k
  • Francois Fornieri

    CEO, Chief Business Development Officer & Executive Director

    • Tenure: 0yrs
  • Koen Hoffman (51yo)

    Independent Director

    • Tenure: 3.3yrs
    • Compensation: €25.00k
  • Gaëtan Servais

    Non-Executive Director

    • Tenure: 0yrs
    • Compensation: €28.75k
  • Guy Debruyne

    Non Executive Director

    • Tenure: 0yrs
    • Compensation: €20.00k
  • Jacques Platieau

    Independent Director

    • Tenure: 0yrs
    • Compensation: €25.00k
  • Freya Loncin (45yo)

    Non-Executive Director

    • Tenure: 3.3yrs
    • Compensation: €20.00k
  • Christiane Malcorps

    Independent Director

    • Tenure: 0yrs
    • Compensation: €25.00k

Company Information

Mithra Pharmaceuticals S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Mithra Pharmaceuticals S.A.
  • Ticker: 1TM
  • Exchange: DB
  • Founded: 1999
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €994.989m
  • Shares outstanding: 37.69m
  • Website: https://www.mithra.com

Number of Employees


Location

  • Mithra Pharmaceuticals S.A.
  • Rue Saint-Georges 5
  • Liège
  • Liège
  • 4000
  • Belgium

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MITRAENXTBR (Euronext Brussels)YesCommon SharesBEEURJun 2015
MITRAbBATS-CHIXE (BATS 'Chi-X Europe')YesCommon SharesGBEURJun 2015
0R91LSE (London Stock Exchange)YesCommon SharesGBEURJun 2015
1TMDB (Deutsche Boerse AG)YesCommon SharesDEEURJun 2015

Biography

Mithra Pharmaceuticals S.A. develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development c ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/12/13 22:09
End of Day Share Price2019/12/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.